ERBB2 and invasive ductal breast carcinoma: In cohort B, patients with the ER− status (positive vs. negative, OR = 0.743, 95% CI = 0.548–1.008, P = 0.056), HER2+ status (positive vs. negative, OR = 1.907, 95% CI = 1.400–2.598, P = 0.000), HbsAg− status (HbsAg + vs. HbsAg−, OR = 0.681, 95% CI = 0.513–0.903, P = 0.008) and invasive ductal carcinoma (IDC) histology (invasive lobular + other vs. invasive ductal, OR = 0.297, 95% CI = 0.126-0.698, P = 0.005) had a higher risk to present with LM.